Volume | 0 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
First Wave BioPharma Inc | FWBI | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
2.96 | 2.96 |
Trades | Shares Traded | Average Volume | 52 Week Range |
---|---|---|---|
0 | 0 | - | 2.3335 - 37.40 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
- | 0 | US$ 2.96 | USD |
First Wave BioPharma Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
2M | 675.00k | - | 0 | -16.1M | -23.86 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
First Wave BioPharma News
Date | Time | Source | News Article |
---|---|---|---|
6/17/2024 | 16:23 | Edgar (US Regulatory) | Form PRER14A - Preliminary Proxy Soliciting materials |
6/14/2024 | 16:15 | Edgar (US Regulatory) | Form 424B3 - Prospectus [Rule 424(b)(3)] |
6/10/2024 | 23:15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness |
6/05/2024 | 16:15 | Edgar (US Regulatory) | Form 8-K - Current report |
5/31/2024 | 16:25 | Edgar (US Regulatory) | Form S-3 - Registration statement under Securities Act of.. |
5/30/2024 | 16:32 | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting.. |
5/30/2024 | 16:18 | Edgar (US Regulatory) | Form 8-K/A - Current report: [Amend] |
5/16/2024 | 06:16 | Edgar (US Regulatory) | Form 8-K - Current report |
5/16/2024 | 06:00 | GlobeNewswire Inc. | First Wave BioPharma Changes Name to Entero Therapeutics |
5/14/2024 | 16:26 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
5/13/2024 | 16:26 | Edgar (US Regulatory) | Form 8-K - Current report |
5/13/2024 | 15:59 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] |
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical FWBI Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
3 Months | 4.10 | 4.58 | 2.3335 | 3.17 | 43,702 | -1.14 | -27.80% |
6 Months | 4.50 | 14.51 | 2.3335 | 5.30 | 481,169 | -1.54 | -34.22% |
1 Year | 35.60 | 37.40 | 2.3335 | 9.14 | 1,323,145 | -32.64 | -91.69% |
3 Years | 483.00 | 686.00 | 2.3335 | 98.16 | 1,412,739 | -480.04 | -99.39% |
5 Years | 483.00 | 686.00 | 2.3335 | 98.16 | 1,412,739 | -480.04 | -99.39% |
First Wave BioPharma Description
First Wave BioPharma Inc is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases. It is advancing a therapeutic development pipeline populated with multiple clinical stage programs built around its two proprietary technologies-niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. |